Please enable JavaScript to continue using this application.

Compare $CRDF vs $RLYB | Chartloom

Compare

$CRDF vs $RLYB

Cardiff Oncology Inc · Rallybio Corp

CRDF

Cardiff Oncology Inc

RLYB

Rallybio Corp

Compare $CRDF vs $RLYB

Comparing Cardiff Oncology Inc and Rallybio Corp

CRDFCardiff Oncology Inc

RLYBRallybio Corp

CRDFCardiff Oncology Inc

Market cap

$84M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

244.08x

Rev growth (TTM)

-7.0%

YTD performance

-59.4%

52W performance

-54.6%

FCF yield

-48.7%

RLYBRallybio Corp

Market cap

$90M

P/E (TTM)

2.17x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-15.1%

YTD performance

200.8%

52W performance

269.6%

FCF yield

29.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CRDF

RLYB

Detailed metrics comparison

CRDF

Cardiff Oncology Inc

RLYB

Rallybio Corp

Market Cap

CRDF$84M

RLYB$90M

Enterprise Value

CRDF$75M

RLYB$-3M

Price

CRDF$1.08

RLYB$17.02

P/E Ratio

CRDFN/A

RLYB2.17x

P/S Ratio

CRDF165.40x

RLYB139.64x

EV/Sales

CRDF147.30x

RLYB-4.09x

EV/EBITDA

CRDF0.00x

RLYB-0.10x

P/B Ratio

CRDF3.28x

RLYB0.96x

P/FCF Ratio

CRDFN/A

RLYB3.38x

EV/FCF

CRDF-1.83x

RLYB-0.10x

PEG Ratio

CRDFN/A

RLYBN/A

Forward P/E (NTM)

CRDFN/A

RLYBN/A

Forward P/S (NTM)

CRDF244.08x

RLYBN/A

Revenue (TTM)

CRDF$508K

RLYB$646K

Revenue Growth (YoY)

CRDF-7.0%

RLYB-15.1%

Forward Rev Growth

CRDF-19.6%

RLYB499.1%

Gross Margin (TTM)

CRDF100.0%

RLYB0.0%

Operating Margin (TTM)

CRDF0.0%

RLYB0.0%

EBITDA Margin (TTM)

CRDF-8251.0%

RLYB-4284.8%

Net Margin (TTM)

CRDF-7889.0%

RLYB7051.2%

FCF Margin (TTM)

CRDF-8054.3%

RLYB4135.0%

Net Income (TTM)

CRDF$-40M

RLYB$46M

FCF (TTM)

CRDF$-41M

RLYB$27M

EPS (TTM)

CRDF-$0.59

RLYB$7.86

ROE (TTM)

CRDF-10308.0%

RLYB68.6%

ROA (TTM)

CRDF-7551.0%

RLYB64.5%

ROIC (TTM)

CRDF-10308.0%

RLYB68.6%

Cash

CRDF$9M

RLYB$93M

Debt

CRDF$0

RLYB$0

Net Cash/Debt

CRDF$9M

RLYB$93M

Current Ratio (TTM)

CRDF3.30x

RLYB27.26x

Quick Ratio (TTM)

CRDF3.21x

RLYB27.01x

Debt/Equity (TTM)

CRDF0.00x

RLYB0.00x

Debt/Assets (TTM)

CRDF0.0%

RLYB0.0%

Interest Coverage (TTM)

CRDFN/A

RLYBN/A

Net Debt/EBITDA (TTM)

CRDF0.00x

RLYB0.00x

Beta

CRDF1.49

RLYB-0.75

52W Performance

CRDF-54.6%

RLYB269.6%

YTD Performance

CRDF-59.4%

RLYB200.8%

% from 52W High

CRDF-67.4%

RLYB-3.2%

% from 52W Low

CRDF42.7%

RLYB363.7%

Asset Turnover (TTM)

CRDF0.01x

RLYB0.01x

FCF Yield (TTM)

CRDF-48.7%

RLYB29.6%

Earnings Yield (TTM)

CRDF-47.7%

RLYB50.5%

Dividend Yield (TTM)

CRDFN/A

RLYBN/A

Rule of 40

CRDF-8,061.3

RLYB4,119.9

EV/GP/RG

CRDFN/A

RLYBN/A

Ticker research

View CRDF research View RLYB research

Metric	CRDF Cardiff Oncology Inc	RLYB Rallybio Corp
Market & Valuation
Market Cap	$84M	$90M
Enterprise Value	$75M	$-3M
Price	$1.08	$17.02
P/E Ratio	N/A	2.17x
P/S Ratio	165.40x	139.64x
EV/Sales	147.30x	-4.09x
EV/EBITDA	0.00x	-0.10x
P/B Ratio	3.28x	0.96x
P/FCF Ratio	N/A	3.38x
EV/FCF	-1.83x	-0.10x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	244.08x	N/A
Revenue & Growth
Revenue (TTM)	$508K	$646K
Revenue Growth (YoY)	-7.0%	-15.1%
Forward Rev Growth	-19.6%	499.1%
Profitability
Gross Margin (TTM)	100.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-8251.0%	-4284.8%
Net Margin (TTM)	-7889.0%	7051.2%
FCF Margin (TTM)	-8054.3%	4135.0%
Net Income (TTM)	$-40M	$46M
FCF (TTM)	$-41M	$27M
EPS (TTM)	-$0.59	$7.86
ROE (TTM)	-10308.0%	68.6%
ROA (TTM)	-7551.0%	64.5%
ROIC (TTM)	-10308.0%	68.6%
Financial Health
Cash	$9M	$93M
Debt	$0	$0
Net Cash/Debt	$9M	$93M
Current Ratio (TTM)	3.30x	27.26x
Quick Ratio (TTM)	3.21x	27.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.49	-0.75
52W Performance	-54.6%	269.6%
YTD Performance	-59.4%	200.8%
% from 52W High	-67.4%	-3.2%
% from 52W Low	42.7%	363.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.01x
FCF Yield (TTM)	-48.7%	29.6%
Earnings Yield (TTM)	-47.7%	50.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-8,061.3	4,119.9
EV/GP/RG	N/A	N/A
Ticker research	View CRDF research	View RLYB research

Valuation

P/E Ratio

RLYB

2.17x

P/S Ratio

RLYB

139.64x

CRDF

165.40x

EV/FCF

CRDF

-1.83x

RLYB

-0.10x

Growth & revenue

Revenue Growth TTM

CRDF

-7.0%

RLYB

-15.1%

Forward Revenue Growth

RLYB

499.1%

CRDF

-19.6%

Profitability & performance

Gross Margin

CRDF

100.0%

RLYB

0.0%

ROE

RLYB

68.6%

CRDF

-10308.0%

FCF Yield %

RLYB

29.6%

CRDF

-48.7%

52-Week Performance

RLYB

269.6%

CRDF

-54.6%

Detailed metrics comparison

CRDF

Cardiff Oncology Inc

RLYB

Rallybio Corp

Market Cap

CRDF$84M

RLYB$90M

Enterprise Value

CRDF$75M

RLYB$-3M

Price

CRDF$1.08

RLYB$17.02

P/E Ratio

CRDFN/A

RLYB2.17x

P/S Ratio

CRDF165.40x

RLYB139.64x

EV/Sales

CRDF147.30x

RLYB-4.09x

EV/EBITDA

CRDF0.00x

RLYB-0.10x

P/B Ratio

CRDF3.28x

RLYB0.96x

P/FCF Ratio

CRDFN/A

RLYB3.38x

EV/FCF

CRDF-1.83x

RLYB-0.10x

PEG Ratio

CRDFN/A

RLYBN/A

Forward P/E (NTM)

CRDFN/A

RLYBN/A

Forward P/S (NTM)

CRDF244.08x

RLYBN/A

Revenue (TTM)

CRDF$508K

RLYB$646K

Revenue Growth (YoY)

CRDF-7.0%

RLYB-15.1%

Forward Rev Growth

CRDF-19.6%

RLYB499.1%

Gross Margin (TTM)

CRDF100.0%

RLYB0.0%

Operating Margin (TTM)

CRDF0.0%

RLYB0.0%

EBITDA Margin (TTM)

CRDF-8251.0%

RLYB-4284.8%

Net Margin (TTM)

CRDF-7889.0%

RLYB7051.2%

FCF Margin (TTM)

CRDF-8054.3%

RLYB4135.0%

Net Income (TTM)

CRDF$-40M

RLYB$46M

FCF (TTM)

CRDF$-41M

RLYB$27M

EPS (TTM)

CRDF-$0.59

RLYB$7.86

ROE (TTM)

CRDF-10308.0%

RLYB68.6%

ROA (TTM)

CRDF-7551.0%

RLYB64.5%

ROIC (TTM)

CRDF-10308.0%

RLYB68.6%

Cash

CRDF$9M

RLYB$93M

Debt

CRDF$0

RLYB$0

Net Cash/Debt

CRDF$9M

RLYB$93M

Current Ratio (TTM)

CRDF3.30x

RLYB27.26x

Quick Ratio (TTM)

CRDF3.21x

RLYB27.01x

Debt/Equity (TTM)

CRDF0.00x

RLYB0.00x

Debt/Assets (TTM)

CRDF0.0%

RLYB0.0%

Interest Coverage (TTM)

CRDFN/A

RLYBN/A

Net Debt/EBITDA (TTM)

CRDF0.00x

RLYB0.00x

Beta

CRDF1.49

RLYB-0.75

52W Performance

CRDF-54.6%

RLYB269.6%

YTD Performance

CRDF-59.4%

RLYB200.8%

% from 52W High

CRDF-67.4%

RLYB-3.2%

% from 52W Low

CRDF42.7%

RLYB363.7%

Asset Turnover (TTM)

CRDF0.01x

RLYB0.01x

FCF Yield (TTM)

CRDF-48.7%

RLYB29.6%

Earnings Yield (TTM)

CRDF-47.7%

RLYB50.5%

Dividend Yield (TTM)

CRDFN/A

RLYBN/A

Rule of 40

CRDF-8,061.3

RLYB4,119.9

EV/GP/RG

CRDFN/A

RLYBN/A

Ticker research

View CRDF research View RLYB research

Metric	CRDF Cardiff Oncology Inc	RLYB Rallybio Corp
Market & Valuation
Market Cap	$84M	$90M
Enterprise Value	$75M	$-3M
Price	$1.08	$17.02
P/E Ratio	N/A	2.17x
P/S Ratio	165.40x	139.64x
EV/Sales	147.30x	-4.09x
EV/EBITDA	0.00x	-0.10x
P/B Ratio	3.28x	0.96x
P/FCF Ratio	N/A	3.38x
EV/FCF	-1.83x	-0.10x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	244.08x	N/A
Revenue & Growth
Revenue (TTM)	$508K	$646K
Revenue Growth (YoY)	-7.0%	-15.1%
Forward Rev Growth	-19.6%	499.1%
Profitability
Gross Margin (TTM)	100.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-8251.0%	-4284.8%
Net Margin (TTM)	-7889.0%	7051.2%
FCF Margin (TTM)	-8054.3%	4135.0%
Net Income (TTM)	$-40M	$46M
FCF (TTM)	$-41M	$27M
EPS (TTM)	-$0.59	$7.86
ROE (TTM)	-10308.0%	68.6%
ROA (TTM)	-7551.0%	64.5%
ROIC (TTM)	-10308.0%	68.6%
Financial Health
Cash	$9M	$93M
Debt	$0	$0
Net Cash/Debt	$9M	$93M
Current Ratio (TTM)	3.30x	27.26x
Quick Ratio (TTM)	3.21x	27.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.49	-0.75
52W Performance	-54.6%	269.6%
YTD Performance	-59.4%	200.8%
% from 52W High	-67.4%	-3.2%
% from 52W Low	42.7%	363.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.01x
FCF Yield (TTM)	-48.7%	29.6%
Earnings Yield (TTM)	-47.7%	50.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-8,061.3	4,119.9
EV/GP/RG	N/A	N/A
Ticker research	View CRDF research	View RLYB research